[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Judd J, et al. Among authors: mamdani h. Mol Cancer Ther. 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13. Mol Cancer Ther. 2021. PMID: 34518295 Free PMC article.
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.
Johnson M, El-Khoueiry A, Hafez N, Lakhani N, Mamdani H, Rodon J, Sanborn RE, Garcia-Corbacho J, Boni V, Stroh M, Hannah AL, Wang S, Castro H, Spira A. Johnson M, et al. Among authors: mamdani h. Clin Cancer Res. 2021 Aug 15;27(16):4521-4530. doi: 10.1158/1078-0432.CCR-21-0194. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083236 Clinical Trial.
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).
Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. Nagasaka M, et al. Among authors: mamdani h. Lung Cancer. 2021 Oct;160:92-98. doi: 10.1016/j.lungcan.2021.08.010. Epub 2021 Aug 27. Lung Cancer. 2021. PMID: 34482103 Free PMC article.
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Nagasaka M, Singh V, Baca Y, Sukari A, Kim C, Mamdani H, Spira AI, Uprety D, Bepler G, Kim ES, Raez LE, Pai SG, Ikpeazu C, Oberley M, Feldman R, Xiu J, Korn WM, Wozniak AJ, Borghaei H, Liu SV. Nagasaka M, et al. Among authors: mamdani h. Clin Lung Cancer. 2022 Jan;23(1):52-59. doi: 10.1016/j.cllc.2021.08.012. Epub 2021 Oct 18. Clin Lung Cancer. 2022. PMID: 34801409 Free article.
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. Khan HY, et al. Among authors: mamdani h. Cancer Res Commun. 2022 May;2(5):342-352. doi: 10.1158/2767-9764.crc-21-0176. Epub 2022 May 10. Cancer Res Commun. 2022. PMID: 35573474 Free PMC article.
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Singh N, et al. Among authors: mamdani h. J Clin Oncol. 2022 Oct 1;40(28):3323-3343. doi: 10.1200/JCO.22.00825. Epub 2022 Jul 11. J Clin Oncol. 2022. Update in: J Clin Oncol. 2023 Feb 10;41(5):e1-e9. doi: 10.1200/JCO.22.02121 Update in: J Clin Oncol. 2023 Apr 10;41(11):e21-e30. doi: 10.1200/JCO.22.02783 Update in: J Clin Oncol. 2023 May 20;41(15):e51-e62. doi: 10.1200/JCO.23.00282 PMID: 35816668 Updated.
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, Heymach JV, Socinski MA, Leu SY, Bhat G, Lebel F, Le X; ZENITH20-4 Investigators. Cornelissen R, et al. Among authors: mamdani h. J Thorac Oncol. 2023 Aug;18(8):1031-1041. doi: 10.1016/j.jtho.2023.03.016. Epub 2023 Mar 21. J Thorac Oncol. 2023. PMID: 36958688 Free article. Clinical Trial.
59 results